These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
212 related articles for article (PubMed ID: 23146970)
1. Healthcare utilization and costs associated with skeletal-related events in prostate cancer patients with bone metastases. Hagiwara M; Delea TE; Saville MW; Chung K Prostate Cancer Prostatic Dis; 2013 Mar; 16(1):23-7. PubMed ID: 23146970 [TBL] [Abstract][Full Text] [Related]
2. Healthcare costs associated with skeletal-related events in breast cancer patients with bone metastases. Hagiwara M; Delea TE; Chung K J Med Econ; 2014 Mar; 17(3):223-30. PubMed ID: 24494707 [TBL] [Abstract][Full Text] [Related]
3. The cost of treatment of skeletal-related events in patients with bone metastases from lung cancer. Delea T; Langer C; McKiernan J; Liss M; Edelsberg J; Brandman J; Sung J; Raut M; Oster G Oncology; 2004; 67(5-6):390-6. PubMed ID: 15713995 [TBL] [Abstract][Full Text] [Related]
4. Payer costs for inpatient treatment of pathologic fracture, surgery to bone, and spinal cord compression among patients with multiple myeloma or bone metastasis secondary to prostate or breast cancer. Barlev A; Song X; Ivanov B; Setty V; Chung K J Manag Care Pharm; 2010; 16(9):693-702. PubMed ID: 21067255 [TBL] [Abstract][Full Text] [Related]
5. The cost of treating skeletal-related events in patients with prostate cancer. Lage MJ; Barber BL; Harrison DJ; Jun S Am J Manag Care; 2008 May; 14(5):317-22. PubMed ID: 18471035 [TBL] [Abstract][Full Text] [Related]
6. The economic burden of skeletal-related events among elderly men with metastatic prostate cancer. Jayasekera J; Onukwugha E; Bikov K; Mullins CD; Seal B; Hussain A Pharmacoeconomics; 2014 Feb; 32(2):173-91. PubMed ID: 24435407 [TBL] [Abstract][Full Text] [Related]
7. The Clinical and Economic Impacts of Skeletal-Related Events Among Medicare Enrollees With Prostate Cancer Metastatic to Bone. McDougall JA; Bansal A; Goulart BH; McCune JS; Karnopp A; Fedorenko C; Greenlee S; Valderrama A; Sullivan SD; Ramsey SD Oncologist; 2016 Mar; 21(3):320-6. PubMed ID: 26865591 [TBL] [Abstract][Full Text] [Related]
8. Canadian health care institution resource utilization resulting from skeletal-related events. Habib MJ; Merali T; Mills A; Uon V Hosp Pract (1995); 2014 Feb; 42(1):15-22. PubMed ID: 24566592 [TBL] [Abstract][Full Text] [Related]
9. Retrospective study of the effect of skeletal complications on total medical care costs in patients with bone metastases of breast cancer seen in typical clinical practice. Delea T; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G J Support Oncol; 2006; 4(7):341-7. PubMed ID: 16892696 [TBL] [Abstract][Full Text] [Related]
10. The economic burden associated with skeletal-related events in patients with bone metastases secondary to solid tumors in Belgium. Body JJ; Chevalier P; Gunther O; Hechmati G; Lamotte M J Med Econ; 2013; 16(4):539-46. PubMed ID: 23425250 [TBL] [Abstract][Full Text] [Related]
11. Economic evaluation of denosumab compared with zoledronic acid in hormone-refractory prostate cancer patients with bone metastases. Xie J; Namjoshi M; Wu EQ; Parikh K; Diener M; Yu AP; Guo A; Culver KW J Manag Care Pharm; 2011 Oct; 17(8):621-43. PubMed ID: 21942303 [TBL] [Abstract][Full Text] [Related]
12. Cost of skeletal-related events in European patients with solid tumours and bone metastases: data from a prospective multinational observational study. Hechmati G; Cure S; Gouépo A; Hoefeler H; Lorusso V; Lüftner D; Duran I; Garzon-Rodriguez C; Ashcroft J; Wei R; Ghelani P; Bahl A J Med Econ; 2013; 16(5):691-700. PubMed ID: 23441975 [TBL] [Abstract][Full Text] [Related]
13. Clinical and economic burden of bone metastasis and skeletal-related events in prostate cancer. Yong C; Onukwugha E; Mullins CD Curr Opin Oncol; 2014 May; 26(3):274-83. PubMed ID: 24626126 [TBL] [Abstract][Full Text] [Related]
14. Economic Evaluation of Treating Skeletal-Related Events among Prostate Cancer Patients. Zhong Y; Valderrama A; Yao J; Donga P; Bilir P; Neumann PJ Value Health; 2018 Mar; 21(3):304-309. PubMed ID: 29566837 [TBL] [Abstract][Full Text] [Related]
15. Retrospective database analysis of the effect of zoledronic acid on skeletal-related events and mortality in women with breast cancer and bone metastasis in a managed care plan. Henk HJ; Kaura S J Med Econ; 2012; 15(1):175-84. PubMed ID: 22017235 [TBL] [Abstract][Full Text] [Related]
16. Impact of skeletal complications on total medical care costs among patients with bone metastases of lung cancer. Delea TE; McKiernan J; Brandman J; Edelsberg J; Sung J; Raut M; Oster G J Thorac Oncol; 2006 Jul; 1(6):571-6. PubMed ID: 17409919 [TBL] [Abstract][Full Text] [Related]
17. Costs of prostate cancer, metastatic to the bone, in the Netherlands. Groot MT; Boeken Kruger CG; Pelger RC; Uyl-de Groot CA Eur Urol; 2003 Mar; 43(3):226-32. PubMed ID: 12600424 [TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States. Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231 [TBL] [Abstract][Full Text] [Related]
19. Assessment of zoledronic acid treatment patterns and clinical outcomes in patients with bone metastases from genitourinary cancers. Henk HJ; Kaura S J Med Econ; 2012; 15(1):185-94. PubMed ID: 22168786 [TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of denosumab compared with zoledronic acid in patients with breast cancer and bone metastases. Xie J; Diener M; Sorg R; Wu EQ; Namjoshi M Clin Breast Cancer; 2012 Aug; 12(4):247-58. PubMed ID: 22694824 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]